Cempra drug is effective, safe for bacterial pneumonia in trial

09/15/2011 | MedCityNews.com

A midstage trial found that Cempra Pharmaceuticals' drug candidate solithromycin is as effective as FDA-approved antibiotic levofloxacin in treating community-acquired bacterial pneumonia, but with less risk of adverse effects. The result supports further evaluation of solithromycin in a Phase III test, said Cempra official David Oldach. The drug is also expected to work against sexually transmitted diseases and Legionnaires' disease.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA